Form 4: Aclaris Therapeutics Interim CEO Neal Walker Reports Stock Transactions
SEC Form 4 Filing
Interim CEO of Aclaris Therapeutics, Neal Walker, reports acquisition and disposal of common stock and restricted stock units on October 1, 2024.
Summary
- On October 1, 2024, Neal Walker, Interim President and CEO of Aclaris Therapeutics, engaged in transactions involving the company's stock.
- Walker acquired 9,467 shares of common stock through the vesting of restricted stock units.
- Simultaneously, Walker disposed of 2,722 shares to cover tax withholding obligations at a price of $1.18 per share.
- Following these transactions, Walker directly owns 1,369,642 shares of Aclaris Therapeutics common stock and 66,267 restricted stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions related to compensation and tax obligations, without indicating any positive or negative outlook for the company.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It allows investors to monitor the actions of key executives and directors, which can offer insights into their perspective on the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 10/01/2024 | Date of stock transactions: acquisition of shares via restricted stock units and disposal of shares for tax obligations. |
| 10/03/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.